宜明昂科-B（01541）今日盘中股价大涨19.52%，引发市场广泛关注。截至上午10点09分，该股报价6.93港元，成交额达2546.88万港元。
此次股价飙升主要源于公司发布的亮眼年度业绩报告。宜明昂科-B全年实现总收入7,415万元，同比增长192倍，收入主要来自授权许可费和合作开发。此外，公司首席执行官田文志增持15万股H股，约占公司已发行股份总数的0.04%，显示出管理层对公司未来发展的信心。
国元国际分析师对宜明昂科-B给予积极评价。他们指出，基于公司CD47核心产品在肿瘤及自免领域的领先优势和广阔市场空间，目前22亿港元的市值严重低估了公司价值。分析师认为，公司拥有7.4亿人民币的现金储备，加上预期的BD收入，足以支持未来的研发推进。国元国际建议投资者积极关注该股。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.